The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Solta Medical's revenues will grow 23.4% and EPS will wither -25.0%.
The average estimate for revenue is $46.0 million. On the bottom line, the average EPS estimate is $0.03.
Last quarter, Solta Medical booked revenue of $34.5 million. GAAP reported sales were 6.4% higher than the prior-year quarter's $32.5 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
Last quarter, non-GAAP EPS came in at -$0.01. GAAP EPS were -$0.04 for Q1 compared to -$0.14 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the preceding quarter, gross margin was 62.8%, 40 basis points better than the prior-year quarter. Operating margin was -9.1%, 180 basis points better than the prior-year quarter. Net margin was -7.5%, much better than the prior-year quarter.
The full year's average estimate for revenue is $177.7 million. The average EPS estimate is $0.14.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 72 members out of 94 rating the stock outperform, and 22 members rating it underperform. Among 14 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), seven give Solta Medical a green thumbs-up, and seven give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Solta Medical is outperform, with an average price target of $4.42.
Is Solta Medical the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Solta Medical to My Watchlist.